Beta Bionics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBNX research report →
About the company
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older.
- CEO
- Sean T. Saint
- IPO
- 2025
- Employees
- 352
- HQ
- Irvine, CA, US
Price Chart
- Market Cap
- $746.85M
- P/E
- -11.21
- P/S
- 6.77
- P/B
- 2.75
- EV/EBITDA
- -11.40
- Div Yield
- 0.00%
- Gross Margin
- 57.15%
- Op Margin
- -70.13%
- Net Margin
- -60.27%
- ROE
- -23.00%
- ROIC
- -27.31%
- Revenue
- $100.25M · 53.94%
- Net Income
- $-73,200,000 · -33.68%
- EPS
- $-1.81 · 78.95%
- Op Income
- $-71,681,000
- FCF YoY
- -8.81%
- 52W High
- $32.71
- 52W Low
- $8.80
- 50D MA
- $12.34
- 200D MA
- $18.12
- Beta
- 3.03
- Avg Volume
- 986.15K
Get TickerSpark's AI analysis on BBNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Feider Stephen | other | 5,104 |
| Jun 29, 26 | Feider Stephen | other | 4,896 |
| Jun 29, 26 | Feider Stephen | sell | 4,896 |
| Jun 26, 26 | Feider Stephen | sell | 5,104 |
| Jun 26, 26 | Feider Stephen | other | 5,104 |
| Jun 29, 26 | Feider Stephen | other | 4,896 |
| Jun 26, 26 | Feider Stephen | other | 4,982 |
| Jun 29, 26 | Feider Stephen | other | 4,896 |
| Jun 26, 26 | Feider Stephen | sell | 5,104 |
| Jun 29, 26 | Feider Stephen | sell | 4,896 |
Our BBNX coverage
Recent articles, reports, and earnings notes.
No research on BBNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BBNX report →Similar companies
Peers in the same neighborhood.